ASCEarnings•globenewswire•
Ascendis Pharma Reports Second Quarter 2025 Financial Results
Sentiment:Negative (20)
Summary
– Q2 2025 revenue of €103.0 million for YORVIPATH® and €50.7 million for SKYTROFA®
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 7, 2025 by globenewswire